checkAd
    Lineage Cell Therapeutics Aktie
    1,0600
     
    USD
    +0,95 %
    +0,0100 USD
    Letzter Kurs 04.05.24 AMEX
    1,0600
     
    USD
    14.200 STK
    Geldkurs 03.05.24
    1,0700
     
    USD
    1.500 STK
    Briefkurs 03.05.24
    ISIN: US53566P1093 · WKN: A2PP89 · SYM: LCTX · USA

    Neueste Nachrichten

    Lineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024
    02.05.24 · Business Wire (engl.) · Lineage Cell Therapeutics
    Lineage Receives Grant From California Institute for Regenerative Medicine (CIRM)
    30.04.24 · Business Wire (engl.) · Lineage Cell Therapeutics
    Lineage Announces Changes to Board of Directors
    29.04.24 · Business Wire (engl.) · Lineage Cell Therapeutics
    Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development
    01.04.24 · Business Wire (engl.) · Lineage Cell Therapeutics
    Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor Symposium
    18.03.24 · Business Wire (engl.) · Lineage Cell Therapeutics
    RG6501 (OpRegen) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit
    13.03.24 · Business Wire (engl.) · Lineage Cell Therapeutics
    RG6501 (OpRegen) Preclinical Engraftment Results to Be Presented at 2024 Association for Research in Vision and Ophthalmology Meeting
    11.03.24 · Business Wire (engl.) · Lineage Cell Therapeutics
    Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
    07.03.24 · Business Wire (engl.) · Lineage Cell Therapeutics
    Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 7, 2024
    29.02.24 · Business Wire (engl.) · Lineage Cell Therapeutics
    Lineage Announces FDA Clearance of IND Amendment for OPC1 Cell Transplant for the Treatment of Spinal Cord Injury
    13.02.24 · Business Wire (engl.) · Lineage Cell Therapeutics
    Lineage Cell Therapeutics Announces Closing of $14.0 Million Registered Direct Offering
    09.02.24 · Business Wire (engl.) · Lineage Cell Therapeutics
    Lineage Cell Therapeutics Announces $14.0 Million Registered Direct Offering
    06.02.24 · Business Wire (engl.) · Lineage Cell Therapeutics